Combination Therapy - Combined Map2k4/map3k1 And Mek/erk Inhibition


Disclosed is a new method of treatment of cancer. Inhibition of the MAP3K1-MAP2K4-JNK pathway, and/or inhibitions of various RTK,and inhibition of the MEK-ERK pathway was found to be useful in the treatment of various cancers, including cancers harboring a KRAS mutation. The treatment is in particular useful in patients harboring wild-type MAP2K4 and MAP3K1 and not responding to inhibitors of the MEK-ERK pathway, in particular MEK inhibitors.

CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Nov 30, 2017
  • Application: May 19, 2017
    WO NL 2017050319 W
  • Priority: May 24, 2016
    NL NL 2016821 A

Download Citation

Sign in to the Lens